GU Cancer ESMO 2024 Highlights

Panelists discuss how overall survival and event-free survival data presented at ESMO 2024 demonstrate promising outcomes in cancer treatment.

Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ESMO 2024, shows potential for improving outcomes in certain cancer treatments.

Panelists discuss how the EORTC-GUCG 1333 (PEACE-3) trial, presented at ESMO 2024, illuminates key findings regarding the study population and primary endpoints in genitourinary cancer research.

Panelists discuss how the CONTACT-02 study results reveal final overall survival data for patients with liver or bone metastases, providing crucial insights into treatment efficacy for these specific metastatic sites.